This suggests that the benefit of SGRP-mediated CD47 blockade combined with CAR-mediated tumor killing relies on CAR target priming, leading to CAR T cell activation and persistence and enhanced myeloid cell infiltration to the brain. The gene discussed is CD47; the disease is neoplasm.